remain cautiou end market
remain cautiou thesi come earn
issu led weaker result outlook expect debat
persist forseeabl futur notabl instrument sale weaken ex-
fx driven inconsist order pattern america pharma
custom ex-fx ceo oconnel cite slow-down purchas small
molecul attribut industri nois around gener price industri
litig industri end market flat ex-fx growth benefit ta
china growth remain mute ex-fx quarter saw return
capit invest gener manufactur though remain cautiou
outlook gener consolid region ultim weaker perform
led reduct guidanc call organ growth vs
previous adj ep prior guid
given cautiou end market outlook lower forecast water
posit revenu forecast consensu pre-earn
product perspect forecast overal organ growth
remain cautiou water end market outlook given weaker lead indic
macro environ industri custom also debat around small molecul
invest pharma custom believ import new product
launch mass spec contribut increment growth instrument end
market perspect forecast assum pharma growth industri
declin flat growth academic/govt custom final cautiou
water elev multipl could compress compani conclud outsiz
level stock repurchas end compani expect buy-back
share model anoth buy-back new
forecast trade ebitda vs
roughli reiter uw rate lower pt
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
underweight specialti provid
life scienc tool market leadership posit
liquid chromatographi thermal analysi
instrument current macro environ
cautiou around exposur industri
custom sale also see risk around
new invest lc exposur small
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
remain cautiou thesi come earn
issu led weaker result outlook expect debat persist
forseeabl futur notabl instrument sale weaken ex-fx driven
inconsist order pattern america pharma custom
ex-fx ceo chri oconnel cite slow-down purchas small molecul
attribut industri nois around gener price industri litig
compani believ order delay expect improv perform
industri end market flat ex-fx headlin result held better
expect growth benefit ta segment wherea water segment
industri custom declin ex-fx china growth remain mute ex-fx
quarter saw return capit invest gener manufactur
though remain cautiou outlook region follow expans
gener consolid program septemb growth weigh
weak food test ultim weaker perform led reduct
guidanc call organ growth vs previous adj
ep prior guid
given cautiou end market outlook lower forecast
posit revenu forecast consensu prior earn product
perspect forecast overal organ growth includ
organ growth instrument sale vs estim flat sale
remain cautiou water end market outlook given weaker lead indic
macro environ industri custom also debat around small molecul
invest pharma custom believ import new product launch
mass spec contribut increment growth instrument forecast also includ
organ growth recur revenu consist outlook modestli
histor level due recent moder instrument sale end
market perspect forecast assum biopharma growth industri
declin flat growth academic/govt custom new adj ep forecast
consensu prior earn forecast repres ep growth
y/i driven predominantli stock buy-back leverag increas
end end final cautiou elev
multipl could compress compani conclud outsiz level stock
repurchas end compani expect repurchas share
model anoth buy-back new forecast water still
trade ebitda vs roughli
reiter underweight rate water lower pt
lower price target reiter underweight rate
pt repres adj ebitda forecast prior
pt repres prior adj ebitda forecast
instrument sale remain weak cautiou could
lead soft recur revenu growth head model
track post ex-fx declin instrument sale compar
growth
specif weak result ex-fx attribut soft septemb
water saw inconsist purchas pharma custom america due
industri nois around gener litig expect instrument sale remain modest
near-term given macro outlook industri custom well continu
pressur gener manufactur fundament concern recur
revenu could continu moder due recent weak capit sale water
biggest busi liquid chromatographi instrument placement uplc/hplc
system yield recur sale chromatographi column chemistri believ
lower instrument sale lead lag impact recur sale roughli one year
chemistri sale recent declin organ growth
forecast organ growth
chemistri sale
water segment organ growth product categori
stack recent result mass spectrometri chromatographi water
notabl laggard versu peer water water segment post averag
roughli organ growth sinc begin compar almost
growth thermo fisher time period growth agil across
organ growth mass spec chromatographi busi
note fiscal year quarter compani
detail pleas see
tool kit
takeaway tool
recent introduc two new high end instrument continu
watch expect contribut growth new cyclic im
synapt xs platform expect begin ship late water also
introduc compani new bioaccord platform design robust mass
spectrometri base approach qa/qc larg molecul workflow
ceo chri oconnel commentari mass spec launch earn
asid macro environ dilig focus excit seri new product
introduct posit compani robust multi-year product cycl impact new product
highli visibl revenu line yet market develop activ progress well
pleas earli custom reaction bioaccord made solid increment progress rel demo quot sale
pipelin third quarter launch cyclic im synapt xs two new tandem quad mass spectromet
well receiv expect see increas sale contribut key product
beyond
mass spec realli headlin year bioaccord game changer realli white space opportun
sens bring highli useabl high qualiti easy-to-us time-of-flight mass spectrometri regul
laboratori space late develop ultim qa/qc chanc person visit three four custom
quarter bought bioaccord feedback posit encourag activ third
quarter big revenu impact third quarter bigger impact sell
encourag number cyclic im quarter even bigger order book synapt xs
system announc launch third quarter ship quarter commun
custom
capit deploy strategi larg favor buy-back would
recommend priorit resourc toward acquisit invest
strateg expand exposur stronger end market given water relationship
pharma biotech sponsor compani right compet win larg
molecul applic compani good start invest behind
bioaccord mass spectrometri analyz design multi-attribut monitor along
bioproduct workflow said believ increas invest need
strengthen increment growth steadili increas compani budget
year rel spend percentag product revenu lag peer
ytd estim expenditur grown ex-fx roughli flat
overal percentag revenu amount increas given declin sale
analyt instrument mm product rev
note thermo fisher ai analyt instrument segment
 mm product sale
 total revenu product fisher product sale barclay corp
one limit factor enter bioproduct market
recent transact price continu move higher view reflect
diverg drug develop trend small larg molecul anoth issu
compani compet consolid best bioproduct
target given scale lead bioproduct compani believ would
difficult match potenti synergi target would either limit abil water
match competitor price would limit potenti deal accret
interestingli updat term credit agreement februari
allow increas leverag materi acquisit
notabl compani amend senior unsecur note agreement allow
compani elect increas permit leverag ratio
period three consecut quarter period time leverag ratio
exce interest payabl senior unsecur note shall increas
note transact inform factual
water commentari earn
barclay meehan given recent growth trend want prod littl bit capit deploy
talk coupl time tuck-in curiou earlier year chang credit agreement allow
increas leverag deal million deal size would consid addit
buy-back plan look asset size curiou addit color could give
around pipelin
ceo chri connel invest intern capabl add portfolio advanc
adjac technolog rigor strateg financi execut framework would character asset
look small mid-siz tuck-in categori certainli lot flexibl
balanc sheet everyth look obvious want make sure opportunist
cfo sherri buck updat agreement recent offer made bring
in-lin languag alreadi far leverag ratio mayb littl bit
housekeep far overal capit structur talk work near term leverag ratio
time certainli right asset make sens us strateg goal strategi
will flexibl chri mention lever got coven place cover
date announcedacquirertargetd evttm fisherlif part fisheradvanc scientif corpor technolog fisherfiness part broader life scienc price net tax barclay corp
guidanc
follow result moder revenu ep
guidanc revenu compani forecast organ growth vs previous
fx forecast headwind revenu growth drive total revenu
year gross margin expect compani state
assumpt unchang prior guidanc announc new
billion expand repurchas plan expect execut upon next two
year guidanc assum billion repurchas includ million
would bring compani weight averag share count
million tax anticip non-gaap tax rate repres
increas midpoint water also lower ep guidanc rang
repres growth y/i foreign exchang
expect headwind ep
guid toward organ revenu growth headwind
fx impli total revenu growth ep expect rang
fx expect headwind ep
revenu million forecast constant
currenc growth lower expect model
midpoint manag guidanc revenu repres growth
y/i ex-fx total growth fx headwind compar
compani guidanc million embed organ growth
fx headwind underli growth across product segment mix notabl
instrument sale weaken organ growth assum includ
declin segment instrument vs ta segment
chemistri sale improv q/q organ growth though comp also
got easier instrument overal y/i ex-fx estim water
instrument ta instrument ex-fx recur revenu grew y/i ex-
fx includ growth servic chemistri
end market perspect biopharma full-year sale end market
deliv ex-fx deceler compani note
global market small molecul pharma applic experienc modest
growth environ water point robust growth larg molecul pharma
highlight excit compani market posit invest lc lc-
ms chemistri industri full-year sale end market remain flat y/i
deceler growth water point strength materi scienc
off-set soft demand food test market particularli china identifi
difficult industri macro environ headwind segment compani
remain confid industri growth opportun point compani newli
launch tandem quad mass spec product final govern academ
full-year sale end market fell ex-fx y/i compar organ growth
water note strong growth biomed research applic europ
off-set soft america china notabl china food segment
remind segment volatil good read-through
coverag given greater instrument exposur govern exposur within
custom class
growth adj day barclay corp
growth across geograph end market mix asia growth driven
stabl trend japan south korea saw solid growth india driven
pharmaceut market off-set industri weak china grew pharmaceut
demand driven impact start phase water also note
food busi weak due broader econom concern china europ
revenu flat solid pharmaceut growth eastern europ off-set declin
western europ america sale declin us declin polit
uncertainti note headwind mexico brazil trend revers
caus decreas spend larg pharmaceut custom gener across lc
lc-m instrument
water geograph divers rev
water revenu breakdown end market
water post weaker organ growth biopharma quarter grow
forecast growth encourag strong biopharma
growth india china off-set soft us europ compani
continu call moder purchas trend among small molecul custom
biopharma exposur robust trend larg molecul custom
confer call water ceo chri oconnel note sale broadli defin
pharmaceut categori increas quarter year-to-d strong growth
china india partial off-set weak europ state earlier
global market small molecul pharmaceut applic current experienc
modest growth environ convers global larg molecul market remain
robust year-to-d sustain consist posit result
support focus invest categori across lc lc-m chemistri
tool average includ agil thermo fisher
academ govern busi declin y/i quarter
healthi academ trend europ partial off-set weak us biomed
chines food sector import rememb academ
govern segment lumpi gener great read-through
peer factor point compar academic/govern exposur
peer
import rememb academ govern segment
lumpi gener great read-through peer factor point
compar academic/govern exposur peer
mix academic/govern exposur broader mani
peer compani nih busi also dod fbi usda
name gener nih repres academ govern revenu
remaind coverag
academ govern smallest custom class repres
total revenu gener academic/govern custom major util
chromatographi system also mean percentag revenu
consum servic stream lower area instead sale gener
driven high-end mass spectrometri placement lumpi quarterli
basi chromatographi largest product segment monitor
biopharma trend better read segment perform addit
natur market academ govern notabl sticki
trend tend vari per quarter
similarli less consum revenu academic/govern
custom class peer water broad consum stream lab
suppli sampl prep like thermo fisher agil drive consist
govern academ exposur
end market perform quarter
revenu grew organ ta divis
water divis revenu growth ex-fx y/i water divis
revenu million came million expect million
declin y/i organ basi revenu increas y/i
estim chemistri revenu growth ex-fx better
organ expect off-set instrument revenu declin
ex-fx expect ex-fx servic revenu increas
market y/i y/i growth y/i y/i growth y/i y/i growth y/i growth barclay corp
organ compar model currenc headwind segment
revenu quarter versu forecast
ta instrument divis revenu increas ex-fx y/i ta
instrument revenu million came million estim
increas organ y/i versu forecast organ currenc
headwind quarter versu estim headwind
water revenu segment million
non-gaap ep increas y/i driven compani buy-back
program share count y/i note ep came toward high end
manag guidanc adjust ep came modestli
estim
water non-gaap ep growth
gross margin came expect lower end
prior guidanc due less fix cost absorpt lower forecast sale volum
gross margin y/i full year guid investor
gross margin
water gross margin annual growth
sg ex-stock comp expens declin y/i revenu
 expens total revenu flat y/i model rel
steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million increas y/i came line
forecast oper margin increas y/i
estim given in-lin ebit top line miss lower anticip sg
expens stock comp drove slight beat revenu vs forecast
 percentag revenu come estim
water ebit margin annual growth
deliv million cffo forecast part
delta driven work capit vs model compani
activ share repurchas repurchas share model
begin announc billion share repurchas
author compani expect net leverag ratio end
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay corp
estestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj net barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
